Seeking Alpha

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's ...
Business Insider

Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the decision to progress IPH6101/SAR443579 into ...
Business Wire

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET ® IPH6501

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of ...
Business Wire

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 ...
Seeking Alpha

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's ...
Oklahoma's News

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual ...

MANNHEIM, Germany, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
BioWorld

NY-303 is first-in-class NK cell engager

Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell ...
Nasdaq

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of ...